The DOI matches its Crossref record; 138 of the 138 references it cites were found in a registry or an index.
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
Open accessAbstract
In light of the large number of studies published since the 2004 update of Schizophrenia Patient Outcomes Research Team psychopharmacological treatment recommendations, we conducted an extensive literature review to determine whether the current psychopharmacological treatment recommendations required revision and whether there was sufficient evidence to warrant new treatment recommendations for prespecified outcomes of interest. We reviewed over 400 articles, which resulted in 16 treatment recommendations: the revision of 11 previous treatment recommendations and 5 new treatment recommendations. Three previous treatment recommendations were eliminated. There were 13 interventions and/or outcomes for which there was insufficient evidence for a treatment recommendation, and a statement was written to summarize the current level of evidence and identify important gaps in our knowledge that need to be addressed. In general, there was considerable consensus among the Psychopharmacology Evidence Review Group and the expert consultants. Two major areas of contention concerned whether there was sufficient evidence to recommend specific dosage ranges for the acute and maintenance treatment of first-episode and multi-episode schizophrenia and to endorse the practice of switching antipsychotics for the treatment of antipsychotic-related weight gain. Finally, there continue to be major gaps in our knowledge, including limited information on (1) the use of adjunctive pharmacological agents for the treatment of persistent positive symptoms or other symptom domains of psychopathology, including anxiety, cognitive impairments, depressive symptoms, and persistent negative symptoms and (2) the treatment of co-occurring substance or medical disorders that occur frequently in individuals with schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Journal of Clinical Psychiatry
(2018) · Journal of Clinical Psychiatry · doi:10.5505/kpd · Cited by 13,651
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
The American Journal of Psychiatry
(2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp · Cited by 2,554
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Discovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative
Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.1 · Cited by 1,428
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393
Second-Generation (Atypical) Antipsychotics and Metabolic Effects: A Comprehensive Literature Review
Newcomer, J. W. (2005) · CNS Drugs · doi:10.2165/00023210-200519001-00001 · Cited by 1,340
Jones, P. B., Barnes, T. R. E., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K. P., Murray, R. M., Markwick, A., & Lewis, S. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1079 · Cited by 1,105
Kahn, R. S., Fleischhacker, W. W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I. P., Gheorghe, M. D., Rybakowski, J. K., Galderisi, S., Libiger, J., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60486-9 · Cited by 1,088
McEvoy, J. P., Lieberman, J. A., Stroup, T. S., Davis, S. M., Meltzer, H. Y., Rosenheck, R. A., Swartz, M. S., Perkins, D. O., Keefe, R. S. E., Davis, C. E., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.600 · Cited by 1,018
Lehman, A. F., Steinwachs, D. M., & The Co-Investigators of the PORT Project (1998) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033302 · Cited by 910
The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements
Dixon, L. B., Dickerson, F., Bellack, A. S., Bennett, M., Dickinson, D., Goldberg, R. W., Lehman, A., Tenhula, W. N., Calmes, C., Pasillas, R. M., et al. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp115 · Cited by 774
Self-citationThe Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2003
Lehman, A. F., Kreyenbuhl, J., Buchanan, R. W., Dickerson, F. B., Dixon, L. B., Goldberg, R., Green-Paden, L. D., Tenhula, W. N., Boerescu, D., Tek, C., et al. (2004) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007071 · Cited by 757
Self-citationKane, J. M., Carson, W. H., Saha, A. R., McQuade, R. D., Ingenito, G. G., Zimbroff, D. L., & Ali, M. W. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0903 · Cited by 624
Csernansky, J. G., Mahmoud, R., & Brenner, R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa002028 · Cited by 605
QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients
Reilly, J., Ayis, S., Ferrier, I., Jones, S., & Thomas, S. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02035-3 · Cited by 602
Lehman, A. F., Steinwachs, D. M., & The Survey Co-Investigators of the PORT Project (1998) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033303 · Cited by 598
Potkin, S. G., Saha, A. R., Kujawa, M. J., Carson, W. H., Ali, M., Stock, E., Stringfellow, J., Ingenito, G., & Marder, S. R. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.7.681 · Cited by 591
The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2009
Kreyenbuhl, J., Buchanan, R. W., Dickerson, F. B., & Dixon, L. B. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp130 · Cited by 499
Self-citationKane, J. M., Eerdekens, M., Lindenmayer, J.-P., Keith, S. J., Lesem, M., & Karcher, K. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.6.1125 · Cited by 489
Sikich, L., Frazier, J. A., McClellan, J., Findling, R. L., Vitiello, B., Ritz, L., Ambler, D., Puglia, M., Maloney, A. E., Michael, E., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08050756 · Cited by 478
Adverse Effects of Atypical Antipsychotics: Differential Risk and Clinical Implications
Haddad, P. M., & Sharma, S. G. (2007) · CNS Drugs · doi:10.2165/00023210-200721110-00004 · Cited by 456
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.2.183 · Cited by 436
Lewis, S. W., Barnes, T. R. E., Davies, L., Murray, R. M., Dunn, G., Hayhurst, K. P., Markwick, A., Lloyd, H., & Jones, P. B. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj067 · Cited by 422
Lieberman, J. A., Tollefson, G., Tohen, M., Green, A. I., Gur, R. E., Kahn, R., McEvoy, J., Perkins, D., Sharma, T., Zipursky, R., et al. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.8.1396 · Cited by 404
McEvoy, J. P., Lieberman, J. A., Perkins, D. O., Hamer, R. M., Gu, H., Lazarus, A., Sweitzer, D., Olexy, C., Weiden, P., & Strakowski, S. D. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1050 · Cited by 377
Harrigan, E. P., Miceli, J. J., Anziano, R., Watsky, E., Reeves, K. R., Cutler, N. R., Sramek, J., Shiovitz, T., & Middle, M. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000104913.75206.62 · Cited by 363
George, T. P., Ziedonis, D. M., Feingold, A., Pepper, W. T., Satterburg, C. A., Winkel, J., Rounsaville, B. J., & Kosten, T. R. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.11.1835 · Cited by 354
Krakowski, M. I., Czobor, P., Citrome, L., Bark, N., & Cooper, T. B. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.6.622 · Cited by 352
Battaglia, J., Moss, S., Rush, J., Kang, J., Mendoza, R., Leedom, L., Dubin, W., McGlynn, C., & Goodman, L. (1997) · The American Journal of Emergency Medicine · doi:10.1016/s0735-6757(97)90119-4 · Cited by 350
Risperidone and Haloperidol in First-Episode Psychosis: A Long-Term Randomized Trial
Schooler, N., Rabinowitz, J., Davidson, M., Emsley, R., Harvey, P. D., Kopala, L., McGorry, P. D., Van Hove, I., Eerdekens, M., Swyzen, W., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.5.947 · Cited by 348
Lieberman, J. A., Phillips, M., Gu, H., Stroup, S., Zhang, P., Kong, L., Ji, Z., Koch, G., & Hamer, R. M. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300157 · Cited by 345
Mortality in Current and Former Users of Clozapine
Walker, A. M., Lanza, L. L., Arellano, F., & Rothman, K. J. (1997) · Epidemiology · doi:10.1097/00001648-199710000-00010 · Cited by 328
Rosenheck, R. (2003) · JAMA · doi:10.1001/jama.290.20.2693 · Cited by 326
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.2.231 · Cited by 322
The metabolic effects of antipsychotic medications
Newcomer, J. W., & Haupt, D. W. (2006) · The Canadian Journal of Psychiatry · doi:10.1177/070674370605100803 · Cited by 315
Pigott, T. A., Carson, W. H., Saha, A. R., Torbeyns, A. F., Stock, E. G., Ingenito, G. G., & Aripiprazole Study Group (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0910 · Cited by 309
Stroup, T. S., Lieberman, J. A., McEvoy, J. P., Swartz, M. S., Davis, S. M., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, C. E., Severe, J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.611 · Cited by 306
Wright, P., Birkett, M., David, S. R., Meehan, K., Ferchland, I., Alaka, K. J., Saunders, J. C., Krueger, J., Bradley, P., San, L., et al. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.7.1149 · Cited by 303
KANE, J., CANAS, F., KRAMER, M., FORD, L., GASSMANNMAYER, C., LIM, P., & EERDEKENS, M. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2006.09.012 · Cited by 296
A placebo controlled trial of bupropion for smoking cessation in schizophrenia
George, T. P., Vessicchio, J. C., Termine, A., Bregartner, T. A., Feingold, A., Rounsaville, B. J., & Kosten, T. R. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01339-2 · Cited by 292
Breier, A., Meehan, K., Birkett, M., David, S., Ferchland, I., Sutton, V., Taylor, C. C., Palmer, R., Dossenbach, M., Kiesler, G., et al. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.5.441 · Cited by 289
The Texas Medication Algorithm Project Antipsychotic Algorithm for Schizophrenia: 2006 Update
Moore, T. A., & Buchanan, R. W. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1115 · Cited by 288
Self-citationSuicidal risk during treatment with clozapine: a meta-analysis
Hennen, J., & Baldessarini, R. J. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2004.05.015 · Cited by 287
Hoffman, R. E., Gueorguieva, R., Hawkins, K. A., Varanko, M., Boutros, N. N., Wu, Y.-T., Carroll, K., & Krystal, J. H. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.03.041 · Cited by 272
Extrapyramidal side-effects of antipsychotics in a randomised trial
Miller, D. D., Caroff, S. N., Davis, S. M., Rosenheck, R. A., McEvoy, J. P., Saltz, B. L., Riggio, S., Chakos, M. H., Swartz, M. S., Keefe, R. S. E., et al. (2008) · British Journal of Psychiatry · doi:10.1192/bjp.bp.108.050088 · Cited by 265
Baker, A., Richmond, R., Haile, M., Lewin, T. J., Carr, V. J., Taylor, R. L., Jansons, S., & Wilhelm, K. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1934 · Cited by 255
Pharmacological Management of Acute Agitation
Battaglia, J. (2005) · Drugs · doi:10.2165/00003495-200565090-00003 · Cited by 254
Davidson, M., Emsley, R., Kramer, M., Ford, L., Pan, G., Lim, P., & Eerdekens, M. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.03.003 · Cited by 249
Aleman, A., Sommer, I. E., & Kahn, R. S. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0310 · Cited by 247
Arterial Stiffness and Stroke in Hypertension: Therapeutic Implications for Stroke Prevention
Laurent, S., & Boutouyrie, P. (2005) · CNS Drugs · doi:10.2165/00023210-200519010-00001 · Cited by 236
Wunderink, L., Nienhuis, F. J., Sytema, S., Slooff, C. J., Knegtering, R., & Wiersma, D. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0502 · Cited by 234
The Texas Medication Algorithm Project Antipsychotic Algorithm for Schizophrenia: 2003 Update
Miller, A. L., Hall, C. S., Buchanan, R. W., Buckley, P. F., Chiles, J. A., Conley, R. R., Crismon, M. L., Ereshefsky, L., Essock, S. M., Finnerty, M., et al. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0408 · Cited by 234
Self-citationAripiprazole for schizophrenia
El-Sayeh, H. G., & Morganti, C. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004578.pub3 · Cited by 230
Marder, S. R., Kramer, M., Ford, L., Eerdekens, E., Lim, P., Eerdekens, M., & Lowy, A. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.01.017 · Cited by 229
Childhood-Onset Schizophrenia: A Double-Blind, Randomized Clozapine-Olanzapine Comparison
Shaw, P., Sporn, A., Gogtay, N., Overman, G. P., Greenstein, D., Gochman, P., Tossell, J. W., Lenane, M., & Rapoport, J. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.7.721 · Cited by 225
Kramer, M., Simpson, G., Maciulis, V., Kushner, S., Vijapurkar, U., Lim, P., & Eerdekens, M. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31802dda4a · Cited by 224
Kumra, S., Kranzler, H., Gerbino-Rosen, G., Kester, H. M., DeThomas, C., Kafantaris, V., Correll, C. U., & Kane, J. M. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.04.043 · Cited by 223
Lesem, M. D., Zajecka, J. M., Swift, R. H., Reeves, K. R., & Harrigan, E. P. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0104 · Cited by 219
Gitlin, M., Nuechterlein, K., Subotnik, K. L., Ventura, J., Mintz, J., Fogelson, D. L., Bartzokis, G., & Aravagiri, M. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.11.1835 · Cited by 217
Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.2.179 · Cited by 207
Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia.
Potkin, S. G., Bera, R., Gulasekaram, B., Costa, J., Hayes, S., Jin, Y., Richmond, G., Carreon, D., Sitanggan, K., & Gerber, B. (1994) · PubMed · Cited by 206
Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia
Swanson, J. W., Swartz, M. S., Van Dorn, R. A., Volavka, J., Monahan, J., Stroup, T. S., McEvoy, J. P., Wagner, H. R., Elbogen, E. B., & Lieberman, J. A. (2008) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.042630 · Cited by 205
Evins, A. E., Cather, C., Deckersbach, T., Freudenreich, O., Culhane, M. A., Olm-Shipman, C. M., Henderson, D. C., Schoenfeld, D. A., Goff, D. C., & Rigotti, N. A. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000162802.54076.18 · Cited by 203
Citrome, L., Volavka, J., Czobor, P., Sheitman, B., Lindenmayer, J.-P., McEvoy, J., Cooper, T. B., Chakos, M., & Lieberman, J. A. (2001) · Psychiatric Services · doi:10.1176/appi.ps.52.11.1510 · Cited by 200
Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets
Chue, P., Eerdekens, M., Augustyns, I., Lachaux, B., Molčan, P., Eriksson, L., Pretorius, H., & David, A. S. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2004.07.003 · Cited by 197
VanderZwaag, C. J., McGee, M., McEvoy, J. P., Freudenreich, O., Wilson, W. H., & Cooper, T. B. (1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.12.1579 · Cited by 193
Evins, A. E., Mays, V. K., Rigotti, N. A., Tisdale, T., Cather, C., & Goff, D. C. (2001) · Nicotine & Tobacco Research · doi:10.1080/14622200110073920 · Cited by 191
Volavka, J., Czobor, P., Nolan, K., Sheitman, B., Lindenmayer, J.-P., Citrome, L., McEvoy, J. P., Cooper, T. B., & Lieberman, J. A. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000117424.05703.29 · Cited by 190
Hasegawa, M., Gutierrez-Esteinou, R., Way, L. E., & Meltzer, H. Y. (1993) · PubMed · Cited by 189
Gitlin, M., Nuechterlein, K., Subotnik, K. L., Ventura, J., Mintz, J., Fogelson, D. L., Bartzokis, G., & Aravagiri, M. (2004) · FOCUS · doi:10.1176/foc.2.1.122 · Cited by 183
Poulet, E., Brunelin, J., Bediou, B., Bation, R., Forgeard, L., Dalery, J., d’Amato, T., & Saoud, M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.10.007 · Cited by 180
Risperidone in the Treatment of First-Episode Psychotic Patients: A Double-Blind Multicenter Study
Emsley, R. A., & Risperidone Working Group (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033413 · Cited by 180
Conventional Antipsychotic Medications for Schizophrenia
Dixon, L. B., Lehman, A. F., & Levine, J. (1995) · Schizophrenia Bulletin · doi:10.1093/schbul/21.4.567 · Cited by 180
Evins, A. E., Cather, C., Culhane, M. A., Birnbaum, A., Horowitz, J., Hsieh, E., Freudenreich, O., Henderson, D. C., Schoenfeld, D. A., Rigotti, N. A., et al. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0b013e3180ca86fa · Cited by 179
Arato, M., O??Connor, R., & Meltzer, H. Y. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200209000-00001 · Cited by 178
Meltzer, H. Y., Bobo, W. V., Roy, A., Jayathilake, K., Aygun, C., Elif, E. A., Yagcioglu, A., & Small, J. G. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0214 · Cited by 176
Daniel, D. G., Potkin, S. G., Reeves, K. R., Swift, R. H., & Harrigan, E. P. (2001) · Psychopharmacology · doi:10.1007/s002130000658 · Cited by 173
Antipsychotic drugs and QT prolongation
Stöllberger, C., Huber, J. O., & Finsterer, J. (2005) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000166405.49473.70 · Cited by 168
Stroup, T. S., Lieberman, J. A., McEvoy, J. P., Swartz, M. S., Davis, S. M., Capuano, G. A., Rosenheck, R. A., Keefe, R. S. E., Miller, A. L., Belz, I., et al. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.3.415 · Cited by 168
George, T. P., Vessicchio, J. C., Sacco, K. A., Weinberger, A. H., Dudas, M. M., Allen, T. M., Creeden, C. L., Potenza, M. N., Feingold, A., & Jatlow, P. I. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.11.002 · Cited by 160
Relationship Between Clinical Efficacy and Clozapine Concentrations in Plasma in Schizophrenia
Hasegawa, M., Gutierrez-Esteinou, R., Way, L. E., & Meltzer, H. Y. (1993) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199312000-00003 · Cited by 155
Cohen, H., Loewenthal, U., Matar, M. A., & Kotler, M. (2001) · The British Journal of Psychiatry · doi:10.1192/bjp.179.2.167 · Cited by 150
Baseline Use of Concomitant Psychotropic Medications to Treat Schizophrenia in the CATIE Trial
Chakos, M., Glick, I. D., Miller, A. L., Hamner, M. B., Miller, D. D., Patel, J. K., Tapp, A. M., Keefe, R. S. E., & Rosenheck, R. A. (2006) · Psychiatric Services · doi:10.1176/appi.ps.57.8.1094 · Cited by 147
Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia
Bitter, I., Dossenbach, M. R. K., Brook, S., Feldman, P. D., Metcalfe, S., Gagiano, C. A., Füredi, J., Bartkó, G., Janka, Z., Bánki, C. M., et al. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.033 · Cited by 147
Olanzapine and haloperidol in first episode psychosis: Two-year data
Green, A. I., Lieberman, J. A., Hamer, R. M., Glick, I. D., Gur, R. C., Kahn, R. S., McEvoy, J. P., Perkins, D. O., Rothschild, A. J., Sharma, T., et al. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.06.021 · Cited by 134
Transcranial magnetic stimulation for auditory hallucinations in schizophrenia
McIntosh, A. M., Semple, D. M., Tasker, K., Harrison, L. K., Owens, D. G. C., Johnstone, E. C., & Ebmeier, K. P. (2004) · Psychiatry Research · doi:10.1016/j.psychres.2004.03.005 · Cited by 133
Gäebel, W., Jänner, M., Frommann, N., Pietźcker, A., Köpcke, W., Linden, M., Müller, P., Müller-Spahn, F., & Tegeler, J. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00182-7 · Cited by 133
Efficacy and Safety of Intramuscular Aripiprazole in Patients With Acute Agitation
Tran-Johnson, T. K., Sack, D. A., Marcus, R. N., et al. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0115 · Cited by 126
Pilowsky, L. S., RING, H. A., Shine, P. J., Battersby, M., & LADER, M. H. (1992) · The British Journal of Psychiatry · doi:10.1192/bjp.160.6.831 · Cited by 124
Andrezina, R., Josiassen, R. C., Marcus, R. N., Oren, D. A., Manos, G., Stock, E. G., Carson, W. H., & Iwamoto, T. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0541-x · Cited by 123
Foster, S., Kessel, J., Berman, M. E., & Simpson, G. M. (1997) · International Clinical Psychopharmacology · doi:10.1097/00004850-199705000-00009 · Cited by 120
Chibbaro, G., Daniele, M., Alagona, G., Pasquale, C. D., Cannavò, M., Rapisarda, V., Bella, R., & Pennisi, G. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.03.052 · Cited by 114
Reid, W. H., Mason, M., & Hogan, T. (1998) · Psychiatric Services · doi:10.1176/ps.49.8.1029 · Cited by 111
Robinson, D. G., Woerner, M. G., Napolitano, B. A., Patel, R. C., Sevy, S. M., Gunduz‐Bruce, H., Soto-Perello, J. M., Mendelowitz, A. J., Khadivi, A., Miller, R., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.12.2096 · Cited by 109
Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior.
Salzman, C., Solomon, D., Miyawaki, E. K., Glassman, R. B., Rood, L., Flowers, E., & Thayer, S. (1991) · PubMed · Cited by 106
McEvoy, J. P., Daniel, D. G., Carson, W. H., McQuade, R. D., & Marcus, R. N. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2007.05.002 · Cited by 106
Stroup, T. S., Lieberman, J. A., McEvoy, J. P., Swartz, M. S., Thomas, S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., DAVIS, C. E., Severe, J. B., et al. (2006) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.4.4.539 · Cited by 102
First-Episode Schizophrenia: A Focus on Pharmacological Treatment and Safety Considerations
Kelly, D. L., Conley, R. R., & Carpenter, W. T. (2005) · Drugs · doi:10.2165/00003495-200565080-00006 · Cited by 98
Self-citationRosa, M. O., & Gattaz, W. F. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1009 · Cited by 98
Maintenance Treatment of Schizophrenia With Risperidone or Haloperidol: 2-Year Outcomes
Marder, S. R., Glynn, S. M., Wirshing, W. C., Wirshing, D. A., Ross, D., Widmark, C., Mintz, J., Liberman, R. P., & Blair, K. E. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.8.1405 · Cited by 98
Impact of Clozapine on Completed Suicide
Sernyak, M. J., Desai, R. A., Stolar, M. J., & Rosenheck, R. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.6.931 · Cited by 98
Спивак, Б., Roitman, S., Vered, Y., et al. (1998) · PubMed · Cited by 97
Baker, R. W., Kinon, B. J., Maguire, G. A., Liu, H., & Hill, A. L. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000085406.08426.a8 · Cited by 97
Dorevitch, A., Katz, N., Zemishlany, Z., Aizenberg, D., & Weizman, A. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.1.142 · Cited by 94
Gäebel, W., Riesbeck, M., Wölwer, W., Klimke, A., Eickhoff, M., von Wilmsdorff, M., JOCKERS-SCHERÜBL, M. C., Kühn, K.-U., Lemke, M., Bechdolf, A., et al. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1116 · Cited by 93
Efficacy and Tolerability of Once-Daily Extended Release Quetiapine Fumarate in Acute Schizophrenia
Kahn, R. S., Schulz, S. C., Palazov, V., Reyes, E. B., Brecher, M., Svensson, O., Andersson, H., & Meulien, D. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0603 · Cited by 92
Tranulis, C., Sepehry, A. A., Galinowski, A., & Stip, É. (2008) · The Canadian Journal of Psychiatry · doi:10.1177/070674370805300904 · Cited by 91
Beasley, C. M., Sutton, V. K., Hamilton, S. H., Walker, D. J., Dossenbach, M. R. K., Taylor, C. C., Alaka, K., Bykowski, D., & Tollefson, G. D. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000095348.32154.ec · Cited by 91
Conley, R. R., Kelly, D. L., Richardson, C. M., Tamminga, C. A., & Carpenter, W. T. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000096246.29231.73 · Cited by 90
Self-citationTwo-Year Follow-Up of a Smoking Cessation Trial in Patients With Schizophrenia
Evins, A. E., Cather, C., Rigotti, N. A., Freudenreich, O., Henderson, D. C., Olm-Shipman, C. M., & GOFF, D. C. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0304 · Cited by 88
Saba, G., Verdon, C.-M., Kalalou, K., Rocamora, J.-F., Dumortier, G., Benadhira, R., Stamatiadis, L., Vicaut, É., Lipski, H., & Januel, D. (2005) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2005.02.008 · Cited by 87
Simpson, G. M., Mahmoud, R. A., Lasser, R. A., Kujawa, M. J., Bossie, C. A., Turkoz, I., Rodriguez, S., & Gharabawi, G. M. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0804 · Cited by 84
Ciapparelli, A., Dell’Osso, L., Pini, S., Chiavacci, M. C., Fenzi, M., & Cassano, G. B. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0502 · Cited by 82
Clozapine Diminishes Suicidal Behavior
Modestin, J., Pian, D. D., & Agarwalla, P. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0418 · Cited by 80
Benzodiazepines combined with neuroleptics for management of severe disruptive behavior
Salzman, C., Green, A. I., Rodriguez‐Villa, F., & Jaskiw, G. I. (1986) · Psychosomatics · doi:10.1016/s0033-3182(86)72734-5 · Cited by 80
Satterthwaite, T. D., Wolf, D. H., Rosenheck, R. A., Gur, R. E., & Caroff, S. N. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n1204 · Cited by 78
A Multidose Study of Haloperidol Decanoate in the Maintenance Treatment of Schizophrenia
Kane, J. M., Davis, J. M., Schooler, N. R., Marder, S. R., Casey, D. E., Brauzer, B., Mintz, J., & Conley, R. R. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.4.554 · Cited by 67
Cutler, A. J., Marcus, R. N., Hardy, S. A., O’Donnell, A., Carson, W. H., & McQuade, R. D. (2006) · CNS Spectrums · doi:10.1017/s1092852900014784 · Cited by 64
Buckley, P. F. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125004510 · Cited by 63
Bender, S., Dittmann-Balçar, A., Schall, U., Wolstein, J. R., Klimke, A., Riedel, M. J., Vorbach, E.-U., Kühn, K.-U., Lambert, M., Dittmann, R., et al. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005924 · Cited by 61
The treatment of recurring auditory hallucinations in schizophrenia with rTMS
Fitzgerald, P. B., Mendieta, J. B., Daskalakis, J. Z., de Castella, A. R., & Kulkarni, J. (2006) · The World Journal of Biological Psychiatry · doi:10.1080/15622970500474705 · Cited by 61
Olanzapine Treatment of Residual Positive and Negative Symptoms
Buchanan, R. W., Ball, M. P., Weiner, E., Kirkpatrick, B. W., Gold, J. M., McMahon, R. P., & Carpenter, W. T. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.1.124 · Cited by 59
Self-citationInvestigation of the Potential of Clozapine to Cause Torsade de Pointes
Warner, B., & Hoffmann, P. (2002) · Adverse Drug Reactions and Toxicological Reviews · doi:10.1007/bf03256196 · Cited by 53
Emerging uses for high-potency benzodiazepines in psychotic disorders.
Ja, B. (1990) · PubMed · Cited by 49
Determining the optimal dose of haloperidol in first-episode psychosis
Oosthuizen, P., Emsley, R. A., Turner, J., & Keyter, N. (2001) · Journal of Psychopharmacology · doi:10.1177/026988110101500403 · Cited by 48 · cited 1×
“comparing haloperidol 2 mg/day to haloperidol 8 mg/ day in first-episode psychosis, Oosthuizen and colleagues reported no between-group differences in overall psychopathology score and clinician global impression improvement scores, whereas the 2-mg/ day group showed significantly lower parkinsonism adverse effect sco…”
BackgroundPsychopharmacology: Underuse of Evidence-Based Treatments in Psychiatry
Fayek, M., Flowers, C., Signorelli, D., & Simpson, G. M. (2003) · Psychiatric Services · doi:10.1176/appi.ps.54.11.1453 · Cited by 43
Thirthalli, J., Bharadwaj, B., Kulkarni, S. D., Kharawala, S., Andrade, C., & Gangadhar, B. N. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.01.003 · Cited by 39
Fatemi, S. H., Stary, J. M., Hatsukami, D. K., & Murphy, S. E. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.02.021 · Cited by 38
Poulet, E., Brunelin, J., Kallel, L., d’Amato, T., & Saoud, M. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07060868 · Cited by 35
Is rTMS efficient as a maintenance treatment for auditory verbal hallucinations? A case report
Poulet, E., Brunelin, J., Kallel, L., Bediou, B., Daléry, J., d’Amato, T., & Saoud, M. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.02.014 · Cited by 31
Electrocardiogram and cardiovascular changes in thioridazine and chlorpromazine poisoning
Strachan, E., Kelly, C. A., & Bateman, D. N. (2004) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-004-0811-7 · Cited by 28
Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia
Park, S., Ross‐Degnan, D., Adams, A. S., Sabin, J., Kanavos, P. G., & Soumerai, S. B. (2005) · The British Journal of Psychiatry · doi:10.1192/bjp.187.2.137 · Cited by 28
Daniel, D. G., Currier, G. W., ZIMBROFF, D. L., ALLEN, M. H., Oren, D. A., MANOS, G., McQuade, R. D., PIKALOV, A. A., & CRANDALL, D. T. (2007) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000271658.86845.81 · Cited by 27
Perry, S. W. (1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.2.276 · Cited by 26
Kongsakon, R., Trinidad-Oñate, P., Chaudhry, H. R., Raza, S. B., Leynes, C. R., Khan, I.-U.-R., Ismail, H. C., Chan, B., Ignacio, J. C., Rodriguez, S. C., et al. (2006) · PubMed · Cited by 12
Second run of transcranial magnetic stimulation has no effects on persistent auditory hallucinations
Chung, Y., Im, E.-S., Cho, G.-H., & Ko, M.-H. (2006) · The World Journal of Biological Psychiatry · doi:10.1080/15622970600954044 · Cited by 11
Chen, R.-Y., Ku, C., Lu, R., & Chou, K. (2002) · Cited by 5
Cited by
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
Liu, N. H., Daumit, G. L., Dua, T., Aquila, R., Charlson, F., Cuijpers, P., Druss, B., Dudek, K., Freeman, M., Fujii, C., et al. (2017) · World Psychiatry · doi:10.1002/wps.20384 · Cited by 865
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 637
Tiihonen, J., Haukka, J., Taylor, M., Haddad, P. M., Patel, M. X., & Korhonen, P. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10081224 · Cited by 619
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Metadata
- Authors
- Buchanan, R. W., Kreyenbuhl, J., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., Himelhoch, S., Fang, B., Peterson, E., Aquino, P. R., & Keller, W.
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-12-02
- Volume
- 36
- Issue
- 1
- Pages
- 71-93
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- OpenAlex
- W2119971225
- Cited by
- 907
- References
- 138
- FWCI
- 32.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.